Lonza Forms New Scientific Advisory Board

September 28, 2020

The board will work with Lonza’s research scientists and product managers to offer guidance on the company’s research and scientific programs for in vitro ADME and toxicology testing.

Lonza announced on Sept. 21, 2020 that it has formed a Scientific Advisory Board consisting of leading industry and academia experts for its Bioscience Business Unit.

According to a company press release, the board will work with Lonza’s research scientists and product managers to offer guidance on the company’s research and scientific programs for in vitro absorption, distribution, metabolism, and excretion (ADME) and toxicology testing.

“The ADME-Tox testing space continues to evolve at an impressive rate, and we see incredibly exciting advancements as drug developers strive for greater efficiency and early predictivity of success,” said Maureen Bunger, senior product manager, Lonza, in the press release. “By convening a select committee of esteemed experts to help guide our innovation programs, we’ll continue to stay ahead of this rapidly changing landscape and maximize our ability to support cost-efficient drug development.”

“Each member of the new Scientific Advisory Board has made significant and extensive contributions to their respective fields, [and] they bring a comprehensive understanding of the myriad challenges faced by early drug discovery researchers,” added Katrin Hoeck, director of Cell Biology, Lonza, in the press release. “The new panel provides a unique opportunity to tap into a reservoir of rich knowledge, and this will ultimately allow us to further strengthen our renowned portfolio of in vitro ADME-Tox testing tools.”

The new board consists of:

  • Antonio Da Silva, PhD, head of Innovation and New Technologies and head of Preclinical Development for Sandoz Biopharmaceuticals.
  • Merrie Mosedale, PhD, a research assistant professor in the Division of Pharmacotherapy and Experimental Therapeutics at the University of North Carolina and assistant director of the Institute for Drug Safety Sciences.
  • Raphael Nir, PhD, co-founder, president, and chief scientific officer of SBH Sciences and SBH Diagnostics.
  • Marian Raschke, PhD, head of Mechanistic Toxicology within Investigational Toxicology at Bayer.

Source: Lonza